PTN - Palatin Technologies' Disappointing Data From Dry Eye Disease Study Stock Plummets | Benzinga
Palatin Technologies Inc (NASDAQ:PTN) shares are trading lower after the company released results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle for dry eye disease (DED).
MELODY-1 had two co-primary efficacy endpoints: one clinical symptom (pain) and one clinical sign (conjunctival lissamine green staining) and multiple other symptom and sign secondary endpoints of DED.
After adjusting the Intent-to-Treat (ITT) analysis for age and gender, PL9643 treatment demonstrated clinically meaningful (visual analog score reduction of >10 points from baseline) and statistically significant results for the co-primary symptom endpoint of pain ...